Bottom line
IXJ vs HRTS: the short answer
IXJ (iShares Global Healthcare ETF) and HRTS (Tema Heart & Health ETF) share a meaningful slice of their top holdings — about 64% by weight.
But IXJ is far broader, holding 124 positions to 45 for HRTS, so beyond the top names it adds exposure HRTS doesn't have.
IXJ is cheaper at 0.38% vs 0.75% — a difference of $37 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +14.9% for IXJ.
Updated Nov 19, 2026
IXJ vs HRTS side by side
| IXJ | HRTS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | Innovator |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.38% | 0.75% |
| Annual cost per $10k | $38 | $75 |
| 10-yr cost on $10k (prospectus) | $480 | $1,168 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +14.9% | +23.6% |
| 5-yr return (annualized) | +6.4% | — |
| 10-yr return (annualized) | +8.2% | — |
| Best quarter | +13.6% | +15.8% |
| Worst quarter | −11.8% | −12.4% |
| Net assets (fund) | $3.8B | $51.9M |
| Number of holdings | 124 | 45 |
| Portfolio turnover | 2% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IXJ | HRTS | Difference |
|---|---|---|---|
| 2025 | +14.9% | +23.6% | −8.8% |
| 2024 | +0.6% | +3.6% | −3.0% |
Source: Fund prospectus bar charts
Holdings overlap
16 of IXJ's top 25 holdings also appear in HRTS's top 25.
| Holding | IXJ | HRTS |
|---|---|---|
| Eli Lilly And Company | 10.93% | 11.52% |
| Johnson & Johnson | 7.04% | 3.59% |
| Abbvie Inc. | 5.12% | 2.40% |
| Unitedhealth Group Incorporated | 4.40% | 5.24% |
| Merck & Co., Inc. | 4.12% | 4.27% |
| Astrazeneca Plc | 3.76% | 4.00% |
| Novartis AG | 3.71% | 3.38% |
| Amgen Inc. | 2.54% | 1.91% |
| Thermo Fisher Scientific Incorporated | 2.42% | 3.97% |
| Abbott Laboratories | 2.05% | 2.61% |
| Gilead Sciences, Inc. | 2.04% | 3.43% |
| Novo Nordisk A/s | 1.99% | 5.24% |
| Vertex Pharmaceuticals Incorporated | 1.64% | 2.93% |
| Danaher Corporation | 1.56% | 2.66% |
| Bristol-myers Squibb Company | 1.53% | 2.09% |
Source: SEC Form N-PORT
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
FAQ
What is the difference between IXJ and HRTS?
Which is cheaper, IXJ or HRTS?
Should I own both IXJ and HRTS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.